Evofem Plans 2019 Refiling For Amphora Based On New 86% Contraception Efficacy

Evofem intends to refile the NDA for its non-hormonal contraceptive Amphora during the second quarter of 2019, after the Phase III AMPOWER study showed 86% efficacy for typical use and 98.7% efficacy when the gel was used as directed.